Aeluma, Inc. announced that President and CEO Jonathan Klamkin terminated his existing Rule 10b5-1 trading arrangement on October 21, 2026. The plan previously authorized the sale of up to 300,000 shares of common stock. Aeluma develops medical devices for minimally invasive surgical procedures.
